Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (64617)	10/5/1999 12:17:00 PM
From: BRANDYBGOOD	Read Replies (1) \| Respond to of 120523

Well, it was sheer bad luck, who knew.... I still made a point off of it, and probably wouldn't have if it wasn't on our list. Even when you're bad, you're good!

To: Jenna who wrote (64617)	10/5/1999 12:32:00 PM
From: lee kramer	Read Replies (1) \| Respond to of 120523

Jenna: #8 down, sure. But it OPENED down. Nobody got hurt because it was on the WL. No scan can protect against a disappointing company announcement. It's gonna happen once in a great while. (Lee)

To: Jenna who wrote (64617)	10/5/1999 4:50:00 PM
From: kendall harmon	Respond to of 120523

CNQR more news after the bell biz.yahoo.com

To: Jenna who wrote (64617)	10/5/1999 6:16:00 PM
From: Jenna	Respond to of 120523

Genset and Janssen Identify a Novel Candidate Gene Associated with Schizophrenia {editors comment: it is said the gene was discovered among the shareholders of GENXY, who have been turning schizophrenic as a result of the new value of their shares of common stock). Reaching a Milestone Towards the Understanding of This Complex CNS Disorder PARIS, Oct. 5 /PRNewswire/ -- Genset (Nasdaq: GENXY; Nouveau Marche: GENSET) announced today that it and the Janssen Research Foundation, a subsidiary of the US pharmaceutical company Johnson & Johnson, reached an important milestone in their schizophrenia research collaboration. Less than two years after receiving a comprehensive collection of clinical samples, Genset successfully identified and delivered to Janssen a novel candidate gene associated with schizophrenia. Financial terms were not disclosed. Said Pascal Brandys, Chairman & CEO of Genset: ''This gene, for which we have filed patent applications, represents an important advance towards understanding the underlying genetic causes of this highly complex and heterogeneous mental disorder. It also provides evidence of the quality of our franchise in gene discovery for CNS disorders. We hope this gene will prove to be a critical proprietary target for our pharmaceutical partner for the rapid development of new and better diagnostic and therapeutic options for schizophrenia, and we are intending to undertake its complete functional characterization in close cooperation with the Janssen Research Foundation.''